Schizophrenia
Conditions
Keywords
Schizophrenia, working memory, N-Acetylcysteine
Brief summary
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
Detailed description
Working memory impairment in Schizophrenia is produced by deficiencies of feedback inhibition of glutamate release, due to low cysteine-glutamate antiporter activity. Because of this mechanism, we are interested in whether acute administration of N-Acetylcysteine will improve performance of patients with schizophrenia on a battery of cognitive tasks utilized to test working memory and other cognitive domains, versus placebo. This pilot study will utilize a randomized, double blind, placebo controlled, crossover design.
Interventions
N-acetylcysteine 1200mg bid for 3 days
Placebo
Sponsors
Study design
Eligibility
Inclusion criteria
* Subjects will be between 18-60 * Meet Diagnostic and Statistical Manual-IV (DSM) criteria for schizophrenia * Be on a stable dose of antipsychotic medication for at least 1 month * Be deemed clinically stable for 3 months by the regular clinical staff
Exclusion criteria
* Current substance or alcohol abuse * Pregnancy * Clozapine treatment * Known sensitivity to sulphur containing compounds * Previous diagnosis of mental retardation * Nitroglycerin use * Asthma diagnosis, verified and treated by a primary care doctor * Use of any other medication that may interact with the study medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BACS Composite RAW Score | Baseline | The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | Baseline | Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better. |
| Brief Visuospatial Memory Test (BVMT) RAW SCORE. | Baseline | Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better. |
| Brief Psychiatric Rating Scale (BPRS)Total Score | Pre Screening | Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Participants This is the overall group of trial participants prior to randomization to either of the two crossover arms in the study. | 28 |
| Total | 28 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Crossover | Withdrawal by Subject | 1 | 0 |
| Initial Assessment | Withdrawal by Subject | 0 | 1 |
| Randomization | Physician Decision | 0 | 1 |
| Randomization | Protocol Violation | 0 | 1 |
| Randomization | Withdrawal by Subject | 2 | 0 |
| Second Crossover | Withdrawal by Subject | 1 | 2 |
Baseline characteristics
| Characteristic | Participants |
|---|---|
| Age, Continuous | 48.64 years STANDARD_DEVIATION 10.58 |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 4 / 11 | 6 / 12 | 4 / 11 | 4 / 11 |
| serious Total, serious adverse events | 0 / 11 | 0 / 12 | 0 / 11 | 0 / 11 |
Outcome results
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Follow Up 1st Leg of Crossover (5 Days)
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 231.58 units on a scale | Standard Deviation 43.25 |
| Placebo | BACS Composite RAW Score | 237.00 units on a scale | Standard Deviation 37.62 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Follow Up (5 days)
Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 234.90 units on a scale | Standard Deviation 35.15 |
| Placebo | BACS Composite RAW Score | 237.77 units on a scale | Standard Deviation 41.37 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Change from Baseline at Follow Up (5 days)
Population: Subjects analyzed are only those with complete data at baseline and 5 day follow up in the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | -7.00 units on a scale | Standard Deviation 13.89 |
| Placebo | BACS Composite RAW Score | -5.59 units on a scale | Standard Deviation 13.63 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Baseline 1st Leg of Crossover
Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 222.75 units on a scale | Standard Deviation 40.72 |
| Placebo | BACS Composite RAW Score | 226.45 units on a scale | Standard Deviation 34.73 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Baseline
Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 229.04 units on a scale | Standard Deviation 38.95 |
| Placebo | BACS Composite RAW Score | 227.83 units on a scale | Standard Deviation 44.44 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Follow Up 2nd Leg of Crossover (5 Days)
Population: Subjects analyzed are those with complete data at follow up and does not include those dropped out from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 238.55 units on a scale | Standard Deviation 46.67 |
| Placebo | BACS Composite RAW Score | 239.33 units on a scale | Standard Deviation 21.85 |
BACS Composite RAW Score
The Brief Assessment of Cognition in Schizophrenia (BACS) is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS composite raw score the total of the raw scores for the 6 subtests of the BACS (Verbal memory, token motor, digit sequencing, verbal fluency, symbol coding and executive functioning). The range, so we could be from 0-435. A high score total score is more favorable and indicates a higher level of cognition. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. It is the raw sum of the test items and higher scores are favorable.
Time frame: Baseline 2nd Leg of Crossover
Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | BACS Composite RAW Score | 229.08 units on a scale | Standard Deviation 53.38 |
| Placebo | BACS Composite RAW Score | 235.91 units on a scale | Standard Deviation 239.33 |
Brief Psychiatric Rating Scale (BPRS)Total Score
Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.
Time frame: Change from PreScreening at End of Trial
Population: Analyses only used matched cases and does not include participants with incomplete data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Psychiatric Rating Scale (BPRS)Total Score | 1.70 units on a scale | Standard Deviation 2.36 |
| Placebo | Brief Psychiatric Rating Scale (BPRS)Total Score | 0.89 units on a scale | Standard Deviation 1.05 |
Brief Psychiatric Rating Scale (BPRS)Total Score
Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.
Time frame: Pre Screening
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Psychiatric Rating Scale (BPRS)Total Score | 30.92 units on a scale | Standard Deviation 7.2 |
| Placebo | Brief Psychiatric Rating Scale (BPRS)Total Score | 28.41 units on a scale | Standard Deviation 7.41 |
Brief Psychiatric Rating Scale (BPRS)Total Score
Brief Psychiatric Rating Scale (BPRS) utilized before and after treatment. BPRS total score is a total of the 18 item scores with a range of 18-126. It is used to measure schizophrenia symptoms and to assess change in them over time. There are 18 symptom sub scores. Each symptom is rated 1-7 (not present to extremely severe) and then all items are summed for the total score. Higher scores indicate more severe symptoms. The BPRS is the gold-standard overall measure of schizophrenia symptoms which will be utilized to demonstrate that the intervention does not cause worsening of the illness symptoms apart from the usual fluctuations of the natural course.
Time frame: End of Trial
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Psychiatric Rating Scale (BPRS)Total Score | 32.80 units on a scale | Standard Deviation 7.31 |
| Placebo | Brief Psychiatric Rating Scale (BPRS)Total Score | 27.78 units on a scale | Standard Deviation 8.91 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Baseline
Population: All participants were analyzed that had baseline data collected (including any that did not complete the time frame).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 20.35 units on a scale | Standard Deviation 6.29 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 20.65 units on a scale | Standard Deviation 7.87 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Follow Up 1st Leg of Crossover (5 Days)
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 16.55 units on a scale | Standard Deviation 6.07 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 18.25 units on a scale | Standard Deviation 7.39 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Baseline 2nd Leg of Crossover
Population: Subjects analyzed are those with complete data at 2nd baseline in the crossover and could include those that had dropped from the study if data was collected prior to drop out.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 21.50 units on a scale | Standard Deviation 7.8 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 20.00 units on a scale | Standard Deviation 7.01 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Follow Up 2nd Leg of Crossover (5 Days)
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 18.82 units on a scale | Standard Deviation 5.69 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 17.44 units on a scale | Standard Deviation 4.85 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Change from Baseline at Follow Up (Baseline - Follow Up)
Population: Subjects analyzed are those with complete data at all timepoints and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 2.57 units on a scale | Standard Deviation 5.13 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 2.77 units on a scale | Standard Deviation 5.76 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Baseline 1st Leg of Crossover
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 20.67 units on a scale | Standard Deviation 5.82 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 19.73 units on a scale | Standard Deviation 16.55 |
Brief Visuospatial Memory Test (BVMT) RAW SCORE.
Brief Visuospatial Memory Test (BVMT) is a measure of visuospatial memory. This task includes three trials of six geometric figures printed in a 2 x 3 array on separate pages. The respondent views the stimulus page for 10 seconds and is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Scoring is based on accuracy of the figure as well as its location on the page. A range of 0-12 per trial is possible(0-36 total). Higher scores are better.
Time frame: Follow Up (5 days)
Population: Subjects analyzed are those with complete data at follow up in the crossover and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 17.90 units on a scale | Standard Deviation 6.29 |
| Placebo | Brief Visuospatial Memory Test (BVMT) RAW SCORE. | 17.68 units on a scale | Standard Deviation 5.86 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Baseline 2nd Leg of Crossover
Population: Subjects analyzed are those with complete data at 2nd baseline in the crossover and could include those that had dropped from the study if data was collected prior to drop out.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.42 units on a scale | Standard Deviation 3.08 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.55 units on a scale | Standard Deviation 2.81 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Baseline 1st Leg of Crossover
Population: Subjects analyzed are those with complete data at baseline prior to dropout from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.33 units on a scale | Standard Deviation 2.84 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.00 units on a scale | Standard Deviation 3.35 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Change from Baseline at Follow Up (5 days)
Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 0.14 units on a scale | Standard Deviation 1.82 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | -0.45 units on a scale | Standard Deviation 2.36 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Follow Up (5 days)
Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.48 units on a scale | Standard Deviation 3.15 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.81 units on a scale | Standard Deviation 3.49 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Baseline
Population: All participants were analyzed that had baseline data collected (including any that did not complete the time frame).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.43 units on a scale | Standard Deviation 2.76 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.22 units on a scale | Standard Deviation 3.15 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Follow Up 1st Leg of Crossover (5 Days)
Population: Subjects analyzed are those with complete data at follow up and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 12.75 units on a scale | Standard Deviation 2.41 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 13.36 units on a scale | Standard Deviation 3.67 |
Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE.
Letter Number Sequencing (LNS) is a brief, standardized executive function task used to assess verbal working memory performance. The test involves a 24-item Experimental Condition, in which participants are read a series of letters and numbers and asked to recite both back in ascending order, with the numbers first and then the letters. Participants receive one point for each correct answer for a range of 0-24. Higher scores are better.
Time frame: Follow Up 2nd Leg of Crossover (5 Days)
Population: Subjects analyzed are those with complete data at 2nd follow up in the crossover and does not include those that had dropped from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 14.27 units on a scale | Standard Deviation 3.41 |
| Placebo | Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. | 14.44 units on a scale | Standard Deviation 1.51 |